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cleases (TALENs) and clustered regularly
interspaced short palindromic repeats
(CRISPR)/CRISPR-associated (Cas) sys-
tems are new classes of genome-editing
tools that target desired genomic sites in
mammalian cells (Miller et al., 2011;
Hockemeyer et al., 2011; Cong et al.,
2013; Mali et al., 2013; Jinek et al.,
2013). TALENs bind as a pair around a
genomic site in which a double-strand
break (DSB) is introduced by a dimer of
FokI nuclease domains. Recently pub-
lished type II CRISPR/Cas systems use
Cas9 nuclease that is targeted to a
genomic site by complexing with a syn-
thetic guide RNA that hybridizes a
20-nucleotide DNA sequence (‘‘proto-
spacer’’) beginning with G and immedi-
ately preceding an NGG motif recognized
by Cas9—constituting a G(N)19NGG
target DNA sequence—resulting in a
DSB three nucleotides upstream of the
NGG motif (Jinek et al., 2012). However
it is generated, the DSB instigates either
nonhomologous end-joining (NHEJ),
which is error-prone and conducive to
frameshift mutations (indels) that knock
out gene alleles, or homology-directed
repair (HDR), which can be exploited
with the use of an exogenously introduced
double-strand or single-strand DNA
repair template to knock in or correct a
mutation in the genome.
We recently reported the use of a
TALEN genome-editing system to rapidly
and efficiently generate mutant alleles of
15 different genes in human pluripotent
stem cells (hPSCs) as a means of per-
forming rigorous disease modeling (Ding
et al., 2013); the proportions of clones
bearing at least one mutant alelle ranged
from 2%–34%. Although one example of
the use of CRISPRs in hPSCs has beenreported (Mali et al., 2013), the efficiency
of allele targeting was only 2%–4%, but
this study, unlike our approach, did not
involve a cell-sorting step.
We sought to compare the relative effi-
cacies of CRISPRs and TALENs targeting
the same genomic sites in the same hPSC
lines with the use of the same delivery
platform as we described previously
(Ding et al., 2013). In the TALEN
genome-editing system, we used the
CAG promoter to cotranslate (via a viral
2A peptide) each TALEN with green fluo-
rescent protein (GFP) or red fluorescent
protein (RFP). For CRISPRs, we subcl-
oned a human-codon-optimized Cas9
gene with a C-terminal nuclear localiza-
tion signal (Mali et al., 2013) into the
same CAG expression plasmid with
GFP, and we separately expressed the
guide RNA (gRNA) from a plasmid with
the human U6 polymerase III promoter
(Mali et al., 2013). The 20 nucleotide pro-
tospacer sequence for each gRNA was
introduced using polymerase chain reac-
tion (PCR)-based methods. Whether us-
ing TALENs or CRISPRs, equal amounts
of the two plasmids were coelectropo-
rated into hPSCs—either 25 mg of
each plasmid or 15 mg of each plasmid
along with 30 mg of a DNA repair template
if attempting knockin—and subjected
to fluorescence-activated cell sorting
(FACS) after 24–48 hr, clonal expansion
of single cells, and screening for muta-
tions at the genomic target site via PCR.
We designed gRNAs matching
G(N)19NGG sequences in seven loci in
six genes—AKT2, CELSR2, CIITA,
GLUT4, LINC00116, and SORT1—that
we had previously successfully targeted
with TALENs (Ding et al., 2013) and in
one locus, in LDLR, that we had not. We
found that in our systemCRISPRs consis-Cell Stem Cetently and substantially outperformed
TALENs across loci and hPSC lines (see
Table S1 available online). The TALENs
yielded clones with at least one mutant
allele at efficiencies of 0%–34%, but
matched CRISPRs yielded mutant clones
at efficiencies of 51%–79% (Table S1).
Just as with TALENs, CRISPRs produced
a variety of indels of sizes ranging
from one nucleotide to several dozen nu-
cleotides in size, centered on the pre-
dicted cleavage sites, suggesting that
NHEJ mutagenesis occurs in the same
way regardless of whether CRISPRs or
TALENs are used. We also found that
CRISPRs readily generated homozygous
mutant clones (7%–25% of all clones;
Table S1) as discerned by sequencing.
We also attempted to knock in E17K mu-
tations into AKT2 using a 67 nucleotide
single-stranded DNA oligonucleotide as
previously described (Ding et al., 2013).
Although the predicted CRISPR cleavage
site was 11 and 13 nucleotides from the
pointmutations, respectively, the CRISPR
yielded knockin clones at a rate of 11%,
whereas TALENs yielded only 1.6%
(Table S1).
We speculate that the superior perfor-
mance of CRISPRs in our system is due
to (1) the Cas9 protein being more highly
expressed and better tolerated than
TALENs in hPSCs, as we routinely
observed earlier (<24 hr versus 48 hr),
and (2) more robust (5%–10% of cells
versus <1%–2% of cells) GFP expression
following electroporation. Other factors
may include intrinsic DNA-unwinding
activity of Cas9 and impaired TALEN
binding on methylated DNA. It is possible
that further optimization of the TALEN
system that we developed could improve
its efficiency and reduce the differential
that we observe.ll 12, April 4, 2013 ª2013 Elsevier Inc. 393
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CRISPRs are worth noting. First, the
requirement for a G(N)19NGG target
sequence somewhat limits site selection.
Because either DNA strand can be tar-
geted, a target sequence occurs on
average every 32 base pairs. This is no
barrier for gene knockout, where any cod-
ing sequence can be targeted, but it may
present difficulties when trying to knock in
or correct a mutation at a specific loca-
tion. However, the requirement for a G at
the start of the protospacer is dictated
by the use of the U6 promoter to express
the gRNA, and alternative CRISPR/Cas
systems can relieve this requirement
(Cong et al., 2013).
Second, the extent of CRISPR off-
target effects remains to be defined.
Previous analyses have suggested that
one-nucleotide mismatches in the first
half of the protospacer are better toler-
ated than mismatches in the second half
(Jinek et al., 2012; Cong et al., 2013).
None of the genomic sequences we
targeted with CRISPRs have perfectly
matched or one-mismatch sequences
elsewhere in the genome. For the AKT2
sequence, there is a two-mismatch
sequence differing at nucleotides 1 and
3, in the more ‘‘tolerant’’ half of the proto-
spacer; we obtained zero clones with
mutations at this potential off-target site,
as compared to 61% at the on-target
site (Table S1), suggesting that at least394 Cell Stem Cell 12, April 4, 2013 ª2013 Elin this instance off-target effects are
not likely to be a significant concern.
Judicious selection of target sites may
well be able to minimize systematic off-
target effects. Nevertheless, clear-cut
determination of the relative risk for both
TALEN- and CRISPR-based approaches
will require a systematic analysis.
It is important to highlight that all
of these genome-editing technology
approaches are still very much in devel-
opment, and more detailed and com-
prehensive studies will be needed to
determine their relative merits in different
experimental circumstances. From a
practical standpoint, CRISPRs are easier
to implement than TALENs, as each
TALEN pair must be constructed de
novo, whereas for CRISPRs the Cas9
component is fixed and the gRNA re-
quires only swapping of the 20-nucleotide
protospacer. Given this consideration
and our observations of substantially
increased efficiency through replacing
TALENs with CRISPRs in an otherwise
identical system, we would suggest that
CRISPRs might well prove to be a very
powerful and broadly applicable tool for
the stem cell community.
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